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Abstract: Probiotic encapsulation technology (PET) has the potential to protect 
microorgansisms and to deliver them into the gut. Because of the promising preclinical and 
clinical results, probiotics have been incorporated into a range of products. However, there 
are still many challenges to overcome with respect to the microencapsulation process and 
the conditions prevailing in the gut. This paper reviews the methodological approach of 
probiotics encapsulation including biomaterials selection, choice of appropriate technology, 
in vitro release studies of encapsulated probiotics, and highlights the challenges to be 
overcome in this area. 
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1. Introduction 
Probiotic survival in products is affected by a range of factors including pH, post-acidification 
during products fermentation, hydrogen peroxide production and storage temperatures [1]. Providing 
probiotic living cells with a physical barrier against adverse conditions is an approach currently 
receiving considerable interest [2]. 
Probiotic encapsulation technology (PET) is an exciting field of biopharmacy that has emerged and 
developed rapidly in the past decade. Based on this technology, a wide range of microorganisms have 
been immobilized within semipermeable and biocompatible materials that modulate the delivery of 
cells. The terms immobilization, entrapment and encapsulation have been used interchangeably in 
most reported literature [3]. While encapsulation is the process of forming a continuous coating around  
an inner matrix that is wholly contained within the capsule wall as a core of encapsulated material, 
immobilisation refers to the trapping of material within or throughout a matrix [3]. Encapsulation tends 
to stabilize cells, potentially enhancing their viability and stability during production, storage and 
handling. An immobilized environment also confers additional protection to probiotic cells during 
rehydration. As the technique of immobilization or entrapment became refined, the cell immobilization 
technology has evolved into cell encapsulation technology [3], which we refer to here as PET. 
The best application of PET in biopharmacy is the controlled and continuous delivery of cells in the 
gut. The potential benefit of this therapeutic strategy is to maintain greater cell viability despite the 
acidity into the stomach. In their viable state, probiotics may exert a health benefice on the host [4,5]. 
One research group showed that alginate could pass through the stomach without any degradation. Gel 
beads formed from this biomaterial were visualized in the human gut by nuclear magnetic resonance 
imaging [6]. The choice of the biomaterial is crucial because it determines the effectiveness of the 
protective device. Beyond this protection, the device must withstand during the passage through the 
stomach, disintegrate in the gut to release the cells. Probiotics are currently encapsulated in polymer 
matrices for various applications. The physical retention of cells in the matrix and their subsequent 
separation is the consequence of the encapsulation technology used. 
Selecting the encapsulation technology is very important. Whereas probiotics are living cells, the 
conditions for implementation of this technology are designed to maintain cell viability, and solvents 
involved in the encapsulation technology must be non-toxic. Furthermore, assess the release conditions 
of encapsulated probiotics in a gastrointestinal tract model is an essential approach, which would give 
an idea of the cells’ behavior. 
This paper reviews the methodological approach of probiotics encapsulation including biomaterials 
selection, choice of appropriate technology, in vitro release studies of encapsulated probiotics, and 
highlights the challenges to be overcome in this area. 
2. Selecting the Biomaterials for Microencapsulation 
The concept of biomaterials usually results in various definitions. A definition often accepted in the 
field of biology and medicine is “any natural material or not, which is in direct contact with a living 
structure and is intended to act with biological systems” [7]. The biomaterials used for probiotics 
encapsulation include natural polymers and synthetic polymers [7]. The terms biocompatible and 
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biodegradable are associated with many of these biomaterials. Biomaterials for probiotics encapsulation 
are in direct contact with the living cells. 
After microencapsulation, the protective device-based biomaterial is intended to be in contact with the 
digestive tract of the host. For all these reasons, much of the general criteria developed for choosing 
biomaterials can be applied. Issues involved when selecting biomaterials for probiotics encapsulation 
are: (a) physicochemical properties (chemical composition, morphology, mechanical strength, stability in 
gastric and intestinal fluids; (b) toxicology assay; (c) manufacturing and sterilization processes. 
Biomaterials are inorganic or organic macromolecules, consisting of repeated chain of monomers 
linked by covalent bonds. Their chemical structure and the conformation of the monomer chains give 
them specific functionality such as ability to form gels [8]. The most common biomaterial used for 
probiotics encapsulation is alginate [9–11]. Other supporting biomaterials include carrageenan, gelatin, 
chitosan, whey proteins, cellulose acetate phthalate, locust bean gum and starches [11]. 
Alginate is a linear polymer of heterogeneous structure composed of two monosaccharide units: 
acid α-L-guluronic (G) and acid β-D-mannuronic (M) linked by β (1–4) glycosidic bonds [12,13]. The 
appearance of G and M monomers in the alginate chains occurs in blocks of alternating sequences, not 
randomly. This arrangement of chains is widely described in the literature and varies from one 
structure to another [13–16]. The M/G ratio determines the technological functionality of alginate. The 
gel strength is particularly important that the proportion of block G is high. Temperatures in the range 
of 60 °C to 80 °C are needed to dissolve alginate in water. Alginate gels are known to be insoluble in 
acidic media [17]. The success of the use of alginate in microencapsulation of probiotics is due to the 
basic protection against acidity it provides to the cells [18–20]. 
Carrageenan are polymers of linear structure consisting of D-galactose units alternatively linked by 
α(1–3) and β(1–4) bonds. Three types of carrageenan are known: kappa (κ) carrageenan, iota (ι) 
carrageenan and lambda (λ) carrageenan [21]. κ-Carrageenan (monosulfated) and ι-carrageenan 
(bisulfated) have an oxygen bridge between carbons 3 and 6 of the D-galactose. This bridge is 
responsible for conformational transitions. It is also responsible for the gelation of κ-carrageenan and 
ι-carrageenan. The λ-carrageenan (trisulfated) that does not have this bridge is unable to gel [22]. 
Carrageenan gelation is induced by temperature changes. A rise in temperature (60 to 80 °C) is 
required to dissolve it and gelation occurs by cooling to room temperature [22,23]. Carrageenan is 
commonly used as food additive; its safety has been approved by several government agencies 
including FDA, codex alimentarius and the joint FAO/WHO food additives [24]. The use of 
carrageenan in microencapsulation of probiotics is due to its capacity to form gel that can entrap the 
cells. However, the cell slurry should be added to the heat-sterilized suspension between 40 and 45 °C, 
otherwise the gel hardens at room temperature [25]. 
Whey proteins are usually used because of their amphoteric character. They can be easily mixed 
with negatively charged polysaccharides such as alginate, carrageenan or pectin [25,26]. When the pH 
is adjusted below their isoelectric point, the net charge of the proteins becomes positive, causing an 
interaction with the negatively charged polysaccharides [17,27,28]. 
Gelatin is frequently used in the food and pharmaceutical industries. It is a protein derived by 
partial hydrolysis of collagen of animal origin. Gelatin has a very special structure and versatile 
functional properties, and forms a solution of high viscosity in water, which sets to a gel during 
cooling [29]. It does not form beads but could still be considered as material for microencapsulation. 
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Chitosan is a positively charged polysaccharide formed by deacetylation of chitin. Its solubility is 
pH-dependent. It is water insoluble at a pH higher than 5.4 [30]. This insolubility presents the 
drawback of preventing the complete release of this biomaterial into the gut which pH is greater than 
5.4 [30]. However, studies have reported the effectiveness of chitosan as a coating agent of alginate gel 
beads [30–32]. Chitosan can form a semipermeable membrane around a negatively charged 
polymer [29]. Whey proteins, gelatin and chitosan are usually used to develop capsules [9] or to coat 
gel beads to improve their stability [11]. 
Cellulose acetate phthalate (CAP) is a polymer insoluble at a pH below 5 but and soluble when the 
pH is greater than 6 [9,11]. This property is essential for probiotics encapsulation because the 
biomaterial must not dissolve into the stomach, but only into the gut. The disadvantage of CAP is that 
it cannot form gel beads by ionotropic gelation; only capsules have been developed by emulsification 
using this biomaterial. CAP is widely used as a coating agent. 
Locust bean gum and starches are usually mixed with alginate or carrageenan to develop gel beads or 
capsules. It appears that specific interactions occur during mixing. The ratio between the proportions of 
each biomaterial before mixing is essential [9]. 
Selecting the appropriate biomaterial is a preliminary study which requires a rigorous methodological 
approach. For probiotics encapsulation, biomaterials such as proteins and polysaccharides must be stable 
in acidic environment and unstable in environment with a pH above 6. This pH is the minimum pH 
found in the intestinal lumen, usually at the beginning of the duodenum [18]. For example, the stability 
of proteins under varying conditions of pH can be assessed by electrophoresis (SDS-PAGE). For 
polysaccharides and other biomaterials treated under various conditions of pH, FTIR-ATR can be used 
to study their stability by determining the any change in its initial structure. Publications have referred to 
the mixture of biomaterials (proteins-polysaccharides or polysaccharide-polysaccharide) to encapsulate 
probiotics [1,2]. However, it would be interesting to elucidate the interactions between these 
biomaterials [17]. Once the biomaterial has been used to develop the protective device, it would also 
be interesting to elucidate the mechanism of resistance of this device in an acidic medium, and its 
disintegration or dissolution in environment with a pH above 6. Searching for new encapsulation 
materials will be of paramount importance in the near future. These materials must meet the 
requirements of non-toxicity, resistance to gastric acidity and compatibility with respect to probiotic 
cells. Several challenges are faced in this area. 
3. Selecting the Microencapsulation Technology 
Most of the reported literature on PET was based on small-scale laboratory procedures. PET requires 
techniques that are gentle and non-aggressive towards the cells. The first encapsulation techniques 
developed to improve the shelf-life of probiotics were to transform cells cultures into concentrated dry 
powder. The techniques of spray-drying, freeze-drying or fluidized bed drying have shown their 
limitations because the cells encapsulated by these techniques are completely released into the product. 
Thereby, the cells are not protected towards the food matrix environment and in the presence of gastric 
fluid or bile [33]. However, probiotics in dried or freeze-dried form exhibit compatibility with 
traditional starter culture such as milk or cheese and have a longer shelf-life compared to their cell 
slurry form [29]. 
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With specific reference to spray-drying, recent publications make reference to its effectiveness in 
protecting probiotic cells [34,35]. This technique commonly used in food industry involves atomization 
of an aqueous or oily suspension of probiotics and carrier material into a drying gas, resulting in rapid 
evaporation of water [29]. Water evaporation is defined as the difference between air inlet temperature 
and air outlet temperature. The spray-drying process is controlled by these temperatures, but also  
by the product feed and the gas flow [29]. Despite the advantages of spray-drying technique, the high 
temperatures needed to facilitate water evaporation reduce the probiotics viability and their activity in the 
final product. The minimum air inlet temperature reported in the literature for probiotic encapsulation is 
100 °C while the maximum is 170 °C. The air outlet temperature vary between 45 °C and 105 °C [29]. 
At these temperatures, it is unlikely that the cells retain all their probiotic activity. Probiotic activity 
must be differentiated from probiotic survival. Probiotic activity takes into account the ability of cells to 
resist to gastrointestinal environment and to adhere to intestinal mucosa [36], so it is important that the 
encapsulation technique does not reduce cell survival and does not inhibit their subsequent activities. 
Providing probiotics with a physical barrier against adverse conditions is an approach receiving 
considerable interest. For this, other techniques have been introduced to further improve the protection 
of probiotics. These techniques were intended to develop gel beads or capsules which were made from 
hydrocolloids by means of extrusion or emulsification techniques [37,38]. Hydrocolloids are aqueous 
dispersion of biomaterials (natural or synthetic polymers). 
The encapsulation process of these two techniques is summarized in Figure 1. 
Figure 1. Diagram of the encapsulation process of probiotics by extrusion technique (a) 
and by emulsification technique (b). 
 
In extrusion technique (a), the hydrocolloid is mixed with probiotics. The resulting mixture is fed 
into an extruder, typically a syringe. Pressure exerted on the syringe plunger drops the contents of the 
Hydrocolloids Probiotics in the form of cell 
slurry or lyophilized powder 
Mixing
Introducing the mixture 
into an extruder 
Scattering the mixture in 
vegetable oil 
Dropping the mixture 
into a gelling solution 
Stabilizing the emulsion 
using emulsifiers 
Recovering of gel Recovering of capsules 
(a) (b)
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syringe into a gelling solution, with gentle stirring. The size and shape of the drops depend on the 
diameter of the needle, and the distance between the needle and the gelling solution. Extrusion is a 
simple and easy implementation, allowing the retention of a high number of cells. Automated 
processes exploiting this principle are available today [39]. 
In the emulsification technique (b), the mixture represents the discontinuous phase. This phase is 
dispersed in a large volume of vegetable oil (continuous phase). The water-in-oil emulsion being 
formed is continuously homogenized by stirring. The stirring speed is a critical step because it affects 
the size and the shape of the droplets formed [40]. Once the emulsion has been broken, the droplets are 
collected by settling. The use of this technique for probiotics encapsulation has been described in the 
literature [40,41]. 
Emulsification generates oily or aqueous droplets commonly named capsules, while the extrusion 
gives gelled droplets called beads. The core of the capsule is liquid while the core of the bead presents 
a porous network [7]. The capsules have sizes that are at least 100 times lower than those of the beads 
[9]. The difference between capsules and beads is shown in Figure 2. Capsules have unequal size and 
shape compared to beads whose shape is uniform. 
Figure 2. (a) Photographs of alginate gel beads and (b) Photographs of alginate  
capsules [39]. 
 
Extrusion is much easier to realize compared to emulsification. Emulsification is more expensive 
because it requires additional raw materials such as vegetable oil and emulsifiers to stabilize the 
emulsion. Emulsification also presents difficulties in implementation including emulsion instability, need 
for vigorous stirring which can be detrimental to cells survival, random incorporation of cells into the 
capsules, and inability to sterilize vegetable oil if you have to work under conditions of strict asepsis. 
From these two techniques are introduced changes to improve beads or capsules stability. Among 
these improvements are coating with others biomaterials [32], cross-linking with organic solvents [42], 
or adding additives or cryoprotectants in the mixture [43]. In the literature, rare are the studies in 
which authors have shown photographs of probiotics entrapped in capsules. Electron microscopy 
(SEM or TEM) is an effective technique to provide evidence of the presence of probiotics in capsules 
or beads and to assess the bacterial loading [20]. 
(a) (b) 
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4. Selecting the in Vitro Conditions for Cells Release 
When probiotics are encapsulated, it is essential to check two conditions. First, ensure that the 
protective device of probiotics is reliable in media simulating the gastric fluid, and then ensure that the 
encapsulated probiotics are released in media simulating the intestinal fluid. 
In the literature, experimental models simulating the gastro-intestinal tract have been described. These 
models evaluate the tolerance of probiotics to acidic media, bile and enzymes. There are generally two 
types of experimental models, known under the names of “conventional model” and “dynamic model”. 
The dynamic model differs from the conventional model because it is semi-automated. Different 
approaches have been proposed. The conventional model simulates either the stomach or the gut. It 
consists of a single reactor (glass container) containing the simulated gastric fluid or the simulated 
intestinal fluid. The dynamic model consists of a series of reactors with respective volume for stomach 
and gut, in which the temperature was maintained at 37 °C and the pH was automatically controlled to 
maintain values of gastric and intestinal pH. All reactors were continuously stirred, and the sterile 
culture medium was fed to gastric reactor by a peristaltic pump which sequentially supplied the gut 
reactor. Flow rate was set to obtain the mean transit time throughout the model [44–47]. 
The in vitro conditions used for the simulation of the stomach are detailed in Table 1. 
Table 1. In vitro conditions most often used to simulate the stomach. 
Gastric fluid pH values Pepsin content (g/L) Exposure time (min) References 
NaCl (2 g/L) 1.55 
2 and 3 
1.55 
2 
0 
0 
0 
0 
180 
120 
120 
60 
[18] 
[19] 
[32] 
[48] 
NaCl (5 g/L) 2 
2 
2 and 3 
3 
3 
3 
60 
180 
240 
[49] 
[50] 
[51] 
NaCl (8.5 g/L) 2.5 
2 and 3 
2 
3 
3 
0 
90 
90 
120 
[52] 
[53] 
[40] 
NaCl (9 g/L) 1.8 3 120 [20] 
HCl (3.65 g/L) 1.1 
1.9 
2 and 3 
0 
0.26 
0 
120 
30 
120 
[54] 
[55] 
[56] 
MRS broth (55 g/L) 2 0 120 [57] 
Peptone broth (7.5 g/L) 2 and 3 0.3 20 [58] 
Cheese broth (8.5 g/L) 2.5 and 3 
2 and 3 
0.016 
0 
120 
180 
[59] 
[60] 
Skimmed milk (12 g/L) 
glucose (2 g/L) yeast 
extracts (1 g/L) and 
cysteine (0.05 g/L) 
2 and 3 
2 and 3 
0 
0 
60 
180 
[10] 
[41] 
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Table 1. Cont. 
Gastric fluid pH values Pepsin content (g/L) Exposure time (min) References 
Glucose (3.50 g/L) NaCl 
(2.05 g/L) KCl (0.37 g/L) 
KH2PO4 (0.60 g/L) CaCl2 
(0.11 g/L) porcine bile 
(0.05 g/L) and lysosyme 
(0.10 g/L) 
2 0.013 90 [61] 
When reading the Table 1, a preference for the NaCl medium was noted. More than half of the 
authors have suggested this. However, concentrations of 2 and 5 g/L of NaCl used seem insufficient to 
maintain the isotonicity of the medium. The American society of microbiology (ASM) recommends 
saline solution at 9 g/L in the microbiological procedures such as microbial cells suspension or 
dilution, and tolerance tests to antimicrobial substances [62]. NaCl provides an isotonic medium that 
maintains the integrity and the viability of the microbial cells. The ASM also reported that phosphate 
can be added to NaCl medium to buffer it. In this case, the concentration of NaCl should be reduced (8 
to 8.5 g/L). Phosphate addition provides a stable pH because of its buffering capacity, which helps to 
maintain cell viability. 
Regarding the gastric fluid pH, it should be noted that the values vary between 1 and 3. This pH 
range covers the values generally observed in human’s stomach [63]. Pepsin was sometimes used as a 
model of gastric enzyme. However, no information is yet available about the true concentration of this 
enzyme in the stomach. This reflects the fact that pepsin is secreted in the form of pepsinogen (inactive 
form) which is then activated in pepsin by the presence of acidic medium [64]. Pepsin activity requires 
a pH under 5.6 [64,65]. Any artificial gastric fluid must include this enzyme in its composition. 
Finally, regarding the exposure time, several values were observed, ranging from 20 min to 240 
min. However, clinical studies have shown that a period of 120 min was sufficient to ensure the gastric 
emptying of 90% of a liquid meal [66] and 60% of a semi-solid meal [66–68]. An exposure time of 
120 min is reasonable for the stay of probiotics in an artificial gastric medium. After a stay of probiotics 
in the stomach, the gut is naturally the second favorite place, so tests are conducted in this part of the 
gastro-intestinal tract. 
The Table 2 presents the in vitro conditions used for the simulation of the gut. 
Table 2. In vitro conditions most often used to simulate the gut. 
Intestinal fluid pH values Bile (g/L) Enzymes (g/L) Pancreatin Trypsin 
Exposure 
time (min) References 
NaHCO3 (25.2 g/L) 6.5 40 3.5 0.1 240 [47] 
NaCl (5 g/L) 8 45 1 0 180 [50] 
Na2HPO4 (2.84 g/L) 7.5 150 1.95 0 360 [55] 
PBS* (1 mol/L) 8 1 1 0 180 [58] 
PBS (np**) 7.4 2 1 0 180 [69] 
* Phosphate Buffer Saline ** Unspecified. PBS defines a medium composed of various salts whose 
proportions vary from one author to another. 
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Bile and pancreatic enzymes are present in the lumen of the gut [70,71], so only studies involving 
the presence of bile and at least one pancreatic enzyme have been emphasized in this review. When 
reading the Table 2, sodium salts are exclusively used as intestinal fluid at various concentrations. The 
term PBS refers to a phosphate buffered saline. In reality, it consists mainly of NaCl in which other 
salts were added: NaCl (8.5 g/L), K2HPO4 (1.1 g/L) and KH2PO4 (0.32 g/L) [72]. Sometimes it 
consists of NaCl (8 g/L), Na2HPO4 (1.44 g/L) and KH2PO4 (0.24 g/L) [62]. One author used it 
incorrectly to refer to an aqueous solution containing only sodium chloride [40]. In many cases, the 
composition of PBS was not mentioned [58,69]. Moreover, it can be a medium in which the salt 
concentrations have been adjusted or supplemented by other salts as needed [73]. 
The pH values used are between 6.5 and 8. These values reflect the pH usually met in the gut [74]. 
Regarding the concentrations of bile and enzymes, no published data allows specifying the exact 
levels, which may explain the variations observed from one author to another. The lack of published 
data on the transit time of the gut may explain the difference observed in the exposure time. Studies 
with radio-labeled food must be conducted to determine this transit time. 
The studies summarized in Tables 1 and 2 clearly show a lack of standard protocol in establishing the 
in vitro conditions for simulating the stomach or the gut. Searching a consensus in the standardization of 
protocols must be in compliance with the conditions prevailing into the gastro-intestinal tract. Type of 
medium and its composition, choice of pH values, exposure time, presence of gastric or intestinal 
enzymes, and presence of bile are the essential factors to be taken into account. These factors should 
reflect reality as much as possible in humans. 
5. Conclusion and Future Perspectives 
PET is widely described in the literature. Since its emergence in the 1990s, tremendous advances have 
been made in this field. PET has been constantly improved, modified and adapted. Despite these 
developments, there are still many challenges in this area, such as developing microencapsulation 
equipment, clarifying microencapsulation procedures, choosing non-toxic materials for probiotics 
encapsulation, developing capsules or beads from polymers adapted to the pH of the digestive tract, 
determining mechanisms of probiotics release from capsules or beads, carrying out in vitro and in vivo 
studies and assessing microencapsulation costs. Many challenges are yet to be overcome and PET 
seems to be not yet well developed, as has been discussed by [2] and [29]. 
The challenge of equipment refers to beads or capsules sizes, which are crucial and should be 
carefully controlled. Small capsules or beads under controlled conditions will not affect the texture of 
food products [29]. Most of the procedures of PET reported involve emulsification technology and 
extrusion technology (also called ionotropic gelation). In emulsification technology, emulsifier or 
surfactant added in vegetable oil was used to promote the capsule. This technique may not be suitable 
for food product development because the residual oil in the encapsulated material is detrimental to 
texture and organoleptic characteristics, and may not be suitable for the development of low-fat dairy 
products [1]. The residual oil, emulsifier and surfactant in the encapsulated material can be toxic to 
probiotic cells and may interact with food components [29]. The resulting capsules are considered to 
be not uniform (Figure 2). This can affect mouth feel and will therefore not be suitable for 
incorporation into food [1]. Research needs should lead to the development of microcapsules using 
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only aqueous gelling without use of emulsifier, surfactant or oil. In terms of handling conditions and 
safety requirements, extrusion seems better to probiotics encapsulation. However, extrusion will face 
the challenge of large-scale production of beads [32]. PET has been applied to dairy products such as 
yogurt, milk, frozen dessert and cheese. The selection is now expanding to fruit juices, cookies and 
chocolate [29]. Recognition of new applications in which food matrices may interact with encapsulated 
probiotics requires additional experimental work. Companies using PET need further expertise to be 
able to estimate the most promising commercial applications. 
Another challenge will be to determine the physicochemical characteristics of encapsulation 
materials to predict their mechanisms of disintegration or dissolution under varying conditions of pH 
and salinity and their interactions with probiotic cells or other components present in the digestive 
tract. PET will be of importance in delivering viable strains of probiotic to consumers in the near 
future. Evidence of this delivering must firstly be provided by the results of in vitro studies, through 
simulation of simple and reproducible gastrointestinal tract models. At this level, the lack of standard 
protocol in the conduct of these tests remains a concern. Efforts should be made in this direction by the 
scientific community. A model of gastro-intestinal tract has been recently published by Gbassi et al. [75]. 
This model regarding its principle and its implementation can serve as a framework for reflection in 
order to understand all aspects of protocols standardization. 
Clinical data resulting from in vivo studies will confirm the delivering of probiotics in the gut, but 
also provide evidence of their health benefits. Legislation in the United State of America allows 
probiotics under dietary supplement health [1]. In Europe, probiotics are defined by their application: 
drug or food [76]. Probiotics used as dietary supplements or functional foods are regulated by food 
legislation. A positive list of health claims with their conditions of use is defined. For any drug claim, 
scientific evidence of the health benefits must be provided. 
The final challenge is to minimize the costs of PET. According to [29], the development of value-
added products such as encapsulated end products will have higher prices. Since product development 
takes both time and financial resources, the microencapsulation phase of probiotics adds additional 
costs to food processing. The costs may vary greatly depending on the technique used and the volume 
of the product. Encapsulation using natural polymers (polysaccharides and proteins) are expensive 
[11,39] and milk proteins are more costly than carbohydrates. The emulsification technique is more 
expensive because it requires additional raw materials such as oil and emulsifiers to stabilize the 
capsules [32]. Spray chilling, rarely reported for probiotics, is considered the least expensive 
encapsulation technology [39]. PET has great potential for the future if the challenges identified are 
resolved by scientists and industrialists. 
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